The impact of cART on hepatic steatosis and fibrosis in treatment-naïve PLwHIV: A prospective cohort study

Abstract

Background

We aimed to determine the effect of combined antiretroviral therapy (cART) on hepatic steatosis and fibrosis in people living with human immunodeficiency virus (PLwHIV).

Methods

In this single-center and prospective cohort study, PLwHIV were evaluated longitudinally by transient elastography at the initiation and 7 months (±1 month) after the cART.

Results

Of the 81 PLwHIV, 28.3% had hepatic steatosis, 40.7% had fibrosis (≥F1), and 24.7% had significant fibrosis (≥F2). In multivariate analysis, body mass index (BMI) (p = .005) and albumin (p = .045) were independent predictors for hepatic steatosis, while aspartate aminotransferase (AST) (p = .041) was an independent predictor for hepatic fibrosis. Control transient elastography was performed in 66 (81.5%) PLwHIV after treatment. Among these patients, the rate of hepatic fibrosis decreased significantly after treatment (43.9% vs 24.2%, p = .017). In the tenofovir alafenamide (TAF)-based regimen, weight (p < .001), BMI (p < .001), waist circumference (p < .001), and total cholesterol (p = .012) increased, while kPA value (p = .002) decreased. In the tenofovir disoproxil fumarate (TDF)-based regimen, controlled attenuation parameter (CAP) value (p = .017) and waist circumference (p = .006) increased. In the lamivudine (LAM)-based regimen, there was no statistically significant change (p > .05).

Conclusion

Hepatic fibrosis regressed with antiretroviral treatments (especially with TAF-based), while the degree of hepatosteatosis progressed (especially with TDF-based). Additionally, weight gain occurred after cART in PLwHIV (especially with TAF-based). Therefore, hepatic steatosis and weight gain in PLwHIV should not be disregarded. In conclusion, PLwHIV on cART need close follow-up for the development of metabolic complications.

Keywords

HIV AIDS transient elastography NAFLD controlled attenuation parameter

Get full access to this article

View all access options for this article.

References

Rodger

Lodwick

Schechter

, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27(6): 973–979.

Fang

Chang

Hsu

, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 2007; 100(2): 97–105.

Matteoni

Younossi

Gramlich

, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116(6): 1413–1419.

Chalasani

Younossi

Lavine

, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1): 328–357.

Younas

Psomas

Reynes

, et al. Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV Med 2016; 17(2): 89–105.

Zevin

McKinnon

Burgener

, et al. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS 2016; 11(2): 182–190.

Lewis

Day

Copeland

. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2(10): 812–822.

Ryom

De Miguel

Cotter

, et al. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. HIV Med 2022; 23(8): 849–858.

Cervo

Shengir

Patel

, et al. NASH in HIV. Curr HIV AIDS Rep 2020; 17(6): 601–614.

10.

Perazzo

Cardoso

Yanavich

, et al. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc 2018; 21(11): e25201.

11.

Maurice

Goldin

Hall

, et al. Increased body mass index and type 2 diabetes are the main predictors of nonalcoholic fatty liver disease and advanced fibrosis in liver biopsies of patients with human immunodeficiency virus monoinfection. Clin Infect Dis 2021; 73(7): e2184–e2193.

12.

Riebensahm

Berzigotti

Surial

, et al. Factors associated with liver steatosis in people with human immunodeficiency virus on contemporary antiretroviral therapy. Open Forum Infect Dis 2022; 9(11): ofac538, Published 2022 Oct 14.

13.

American Diabetes Association . Standards of care in Diabetes—2023 abridged for primary care providers. Clin Diabetes 2022; 41(1): 4–31, [published correction appears in Clin Diabetes. 2023 Spring;41(2):328].

14.

Alberti

Eckel

Grundy

, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640–1645.

15.

Williams

Mancia

Spiering

, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021–3104, [published correction appears in Eur Heart J. 2019 Feb 1;40(5):475].

16.

Jung

Kim

. Clinical applications of transient elastography. Clin Mol Hepatol 2012; 18(2): 163–173.

17.

Karlas

Petroff

Sasso

, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017; 66(5): 1022–1030.

18.

Tsochatzis

Gurusamy

Ntaoula

, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54(4): 650–659.

19.

Younossi

Koenig

Abdelatif

, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64(1): 73–84.

20.

Vuille-Lessard

Lebouché

Lennox

, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS 2016; 30(17): 2635–2643.

21.

Rockstroh

. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in HIV. Curr HIV AIDS Rep 2017; 14(2): 47–53.

22.

Chihota

Riebensahm

Muula

, et al. Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia. BMJ Open Gastroenterol 2022; 9(1): e000945.

23.

Worm

Friis-Møller

Bruyand

, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24(3): 427–435.

24.

Nguyen

Peer

Mills

, et al. A meta-analysis of the metabolic syndrome prevalence in the global HIV-Infected population. PLoS One 2016; 11(3): e0150970, Published 2016 Mar 23.

25.

Wand

Calmy

Carey

, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21(18): 2445–2453.

26.

Sulkowski

Mehta

Torbenson

, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19(6): 585–592.

27.

Venter

WDF

Moorhouse

Sokhela

, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med 2019; 381(9): 803–815.

28.

Hocqueloux

Menard

Arvieux

, et al. Weight gain following the single substitution of Tenofovir Disoproxil fumarate by Tenofovir Alafenamide in HIV-infected people from the French Dat’AIDS cohort: a propensity score-matched analysis. HIV Med 2023. DOI: 10.1111/hiv.13488, [published online ahead of print, 2023 Apr 4].

29.

Powell-Wiley

Poirier

Burke

, et al. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation 2021; 143(21): e984–e1010.

30.

Arribas

Thompson

Sax

, et al. Brief report: randomized, double-blind comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), each coformulated with Elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr 2017; 75(2): 211–218.

31.

Sun

, et al. Higher risk of dyslipidemia with coformulated Elvitegravir, Cobicistat, emtricitabine, and Tenofovir Alafenamide than Efavirenz, lamivudine, and Tenofovir disoproxil fumarate among antiretroviral-naive people living with HIV in China. J Acquir Immune Defic Syndr 2022; 91(S1): S8–S15.

32.

Trizzino

Gaudiano

Arena

, et al. Switching to Bictegravir/Emtricitabine/Tenofovir alafenamide fumarate regimen and its effect on liver steatosis assessed by Fibroscan. Viruses 2025; 17(3): 440, Published 2025 Mar 19.

33.

Bischoff

Schwarze-Zander

, et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). eClinicalMedicine 2021; 40: 101116, Published 2021 Sep 5.

34.

Perna

Carleo

Mascolo

, et al. Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model. AIDS 2023; 37(4): 561–570.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.52 MB